Associations between urinary glycosaminoglycans and onset of acute respiratory distress syndrome in sepsis patients: a prospective exploratory study

尿糖胺聚糖与脓毒症患者急性呼吸窘迫综合征发作的相关性:一项前瞻性探索性研究

阅读:1

Abstract

The aim of the current study was to explore the association between urinary glycosaminoglycans and the onset of acute respiratory distress syndrome (ARDS) in sepsis patients. We conducted a prospective cohort study of 49 sepsis patients and collected clinical characteristics, urine, and blood samples within 24 h of admission to the Surgical Intensive Care Unit (SICU) of Peking University Third Hospital. Samples from patients who did not develop ARDS were collected from day 1 to day 7 after SICU admission, while samples from patients who developed ARDS were collected from day 1 to the day of onset, forming time-series data. A liquid chromatography-mass spectrometry (LC-MS) system was used to determine urinary dermatan sulfate (DS), chondroitin sulfate (CS), and heparan sulfate (HS) concentrations; enzyme-linked immunosorbent assay (ELISA) and cytometric bead array (CBA) were used to measure plasma inflammatory factors. The endpoint was the onset of ARDS. We used generalized estimating equations to identify associations between urinary glycosaminoglycans and ARDS onset in sepsis patients. Twenty-two of the 49 sepsis patients developed ARDS, and 132 plasma samples and 132 urine samples were obtained. Between the ARDS and non-ARDS groups, sex, pneumonia, Acute Physiology and Chronic Health Evaluation II (APACHE II), Lung Injury Prediction Score (LIPS), and PaO(2)/FiO(2) showed statistically significant differences. Generalized estimating equations showed that DS and tumor necrosis factor-α (TNF-α) were independently associated with ARDS onset in sepsis patients, but their generalizability across ARDS subtypes warrants further validation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。